Psoriasisli Hastaların COVID-19 Pandemisi Döneminde Tedavilerinde ve Takiplerinde Yaşadıkları Zorluklar: Psoriasisli 57 Hasta ile Yapılan Anket Çalışması

Yıl 2022, Cilt: 7 Sayı: 3, 72 - 76, 01.12.2022

Atıl Avcı , Deniz Avcı , Mustafa Atasoy , Kemal Özyurt , Ragıp Ertaş

Öz

Özet
Amaç : Covid-19 pandemisi sürecinde psoriasisli hastaların tedavilerine düzenli devam edip etmediklerini ve kullandıkları tedavilerde aksamalar olup olmadığını araştırdık.
Yöntem : Deri ve Zührevi Hastalıklar “Kronik Hastalıklar Polikliniği”'nde izlenen psoriasis ve psoriatik artiritli 57 hastanın tedavi ve takiplerinde pandemik sürecin etkilerini 13 sorudan oluşan anket formu ile değerlendirdik.
Bulgular : Hastaların yaş ortalaması 46,3 ± 13,6 yıl idi. Hastaların pandeminin başlangıcına yakın dönemlerden itibaren polikliniğe enson gelmelerinden başlangıç alan ortanca tedavi süreleri 1,0 (0,0 – 12,0) ay idi. Tedavisiz geçen sürenin uzunluğu erkek ve kadınlar arasında istatistiksel olarak benzerdi. Pandemi döneminde hastaların % 42,1’i (n=24) tedaviye devam edebildiğini, % 57,9 u (n=33) ise edemediğini belirtti. Pandemi öncesinde kaydedilmiş olan PASI değerleri ortancası 0,0 (0,0 – 22,0) idi. Covid-19 pandemisi sürecinde ilk başvurusunda hesaplanan PASI’nin ortanca değeri ise 2,4 (0,0 – 22,0) idi. PASI değerlerindeki bu değişim istatistiksel olarak da anlamlı idi (p<0,001).
Sonuç : Yaptığımız, Covid-19 sürecinde psoriasisli hastaların randevularına ve tedavilerine uyum anket çalışmasında, hastaların yaklaşık yarısının tedavilerinde aksamalar olduğunu gördük. Tedavisi aksayan hastalar kontrole gelip tedavilerini yeniden düzenletemedikleri için çoğunlukla önceki tedavilerini sürdürme yoluna gitmişlerdi.
Anahtar kelimeler : Psoriasis, covid-19, kronik hastalıklar, pandemi


DIFFICULTIES EXPERIENCED BY PATIENTS WITH PSORIASIS IN THEIR TREATMENTS AND FOLLOW-UPS DURING THE COVID-19 PANDEMIC: QUESTIONNAIRE OF 57 PATIENTS WITH PSORIASIS
Summary:
Aim: During the Covid-19 pandemic process, we investigated whether patients with psoriasis could be able to continue their treatment regularly and whether there were disruptions in their treatments.
Patients and Methods: We evaluated the effects of the pandemic process in the treatment and follow-up of 57 psoriasis and psoriatic arthritis patients who were followed up in the Chronic Diseases Polyclinic of Dermatology and Venereal Diseases, using a questionnaire form consisting of 13 questions.
Results: The mean age of the patients was 46.3 ± 13.6 years. The median duration of treatment of the patients was 1.0 (0.0 - 12.0) months. The length of time without treatment was statistically similar between men and women. During the pandemic period, 42.1% (n = 24) of the patients stated that they could continue the treatment, while 57.9% (n = 33) could not. The median of PASI values recorded before the pandemic was 0.0 (0.0 - 22.0). . During the Covid-19 pandemic, the median value of the PASI calculated in the first application was 2.4 (0.0 - 22.0). This change in PASI values was statistically significant (p <0.001).
Conclussions: In the survey study we conducted, compliance with the appointments and treatments of patients with psoriasis during the Covid-19 process, we showed that approximately half of the patients had disruptions in their treatment. The patients whose treatment was disrupted mostly used their previous treatments.

Anahtar Kelimeler

Psoriasis, covid-19, chronic diseases, pandemics

Destekleyen Kurum

yoktur

Proje Numarası

yoktur

Kaynakça

• 1. Dünya Sağlık Örgütü. Archived: WHO Timeline - COVID-19İ [İnternet]. İsviçre: Dünya Sağlık Örgütü [alıntı 2021 Mart 2021]. Erişim adresi: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19
• 2. Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy Eur J Allergy Clin Immunol. 2021; 76(3): 816–30.
• 3. Özyurt K, Ertaş R, Ertaş ŞK. Treatment of Psoriatic Arthritis and Turkish Psoriasis Treatment Guideline-2016. Vol. 3, Journal of Anatolian Medical Research. 2018 Dec.
• 4. Hsu LN, Armstrong AW. Psoriasis and autoimmune disorders: A review of the literature. J Am Acad Dermatol. 2012; 67(5): 1076–9.
• 5. Sarli B, Dogan Y, Baktir AO, Saglam H, Arinc H, Kurtul S, et al. Heart Rate Recovery Is Impaired in Patients with Psoriasis. Med Princ Pract. 2013; 22(6): 567–70.
• 6. Boehncke WH, Schön MP. Psoriasis. Vol. 386, The Lancet. Lancet Publishing Group; 2015. p. 983–94.
• 7. Özyurt K, Ertaş R, Atasoy M. Biologics for psoriasis: What is new? Dermatol Ther. 2019; 32(3).
• 8. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: Epidemiology, clinical features, and quality of life. In: Annals of the Rheumatic Diseases. Ann Rheum Dis; 2005.
• 9. Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries. J Invest Dermatol. 2015; 135(4): 984–91.
• 10. Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. Vol. 31, Journal of the European Academy of Dermatology and Venereology. Blackwell Publishing Ltd; 2017. p. 798–807.
• 11. Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. 2018;
• 12. Ozyurt K, Ertas R, Avcı A, Ulas Y, Akkuş MR, Atasoy M. Chronic Skin Disease Unit and Internal Counseling in an Outpatient Dermatology Clinic: Collaboration of Dermatologists in Dermatology Practice. İstanbul Kanuni Sultan Süleyman Tıp Derg. 2020;
• 13. Özyurt K, Avcı A, Ertaş R, Ulaş Y, Akkuş MR, Özlü E, et al. Psortaksis: Kayseri sağlık uygulama ve araştırma merkezi dermatoloji kliniği’nde kullanılan yeni bir psoriasis hasta kayıt sistemi. Turk Dermatoloji Derg. 2018; 12(1): 23–7.
• 14. Avcı A, Eğitim ve Araştırma Hastanesi K, Kliniği D, Tarihi G, Hastalıkları Kliniği İ, Atıl Avcı T, et al. Özgün Araştırma / Original Investigation 66.
• 15. Ihtatho D, Ahmad Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for PASI scoring. In: Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings [Internet]. Annu Int Conf IEEE Eng Med Biol Soc; 2007 [cited 2021 Apr 19]. p. 3446–9. Available from: https://pubmed.ncbi.nlm.nih.gov/18002738/
• 16. Engler D, Chezuba HP, Masuku P. Psoriasis. Vol. 84, SA Pharmaceutical Journal. Medpharm Publications; 2017. p. 38–42.
• 17. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 ; 20(18): 4347.
• 18. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2007; 298(7): 321–8.
• 19. Gerdes S, Mrowietz U, Boehncke WH. Komorbidität bei Psoriasis vulgaris. Hautarzt. 2016; 67(6): 438–44.
• 20. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6): 1475.
• 21. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011; 303(1): 1–10.
• 22. Peloso RM, Pini NIP, Neto DS, Mori AA, de Oliveira RCG, Valarelli FP, et al. How does the quarantine resulting from COVID-19 impact dental appointments and patient anxiety levels? Braz Oral Res. 2020; 34.
• 23. Białynicki-Birula R, Siemasz I, Otlewska A, Matusiak Ł, Szepietowski JC. Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland. Dermatol Ther. 2020; 33(4): e13738–e13738.
• 24. Reznik A, Gritsenko V, Konstantinov V, Khamenka N, Isralowitz R. COVID-19 Fear in Eastern Europe: Validation of the Fear of COVID-19 Scale. International Journal of Mental Health and Addiction. Springer; 2020. p. 1.
• 25. Mendlovic J, Weiss G, Da’as N, Yinnon A, Katz DE. Internal medicine patients admitted without COVID‐19 during the outbreak. Int J Clin Pract. 2020; 74(12): e13630.